Covered recipient · General Payments record
VENKAT PAVAN R KANCHARLA
Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2021 · Entire year
$8,764.77
260 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2021 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $7,581.55 | 246 |
| Long term medical supply or device loan | $1,014.85 | 11 |
| Education | $168.37 | 3 |
By paying entity
PY2021 · entire year · sorted by reported total
Page 2 of 6; records 51–100 of 260 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
VENKAT PAVAN R KANCHARLA
NPI 1205091758 · CMS profile ID 99298
Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology
PALM BAY, FL
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 6; records 51–100 of 260 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1205091758?year=2021&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- VENKAT PAVAN R KANCHARLA, NPI 1205091758, CMS profile ID 99298. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 6; records 51–100 of 260 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1205091758?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- APA 7
- IndustryPayments. (2026). VENKAT PAVAN R KANCHARLA, NPI 1205091758, CMS profile ID 99298. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 6; records 51–100 of 260 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1205091758?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- Bluebook
- VENKAT PAVAN R KANCHARLA, NPI 1205091758, CMS profile ID 99298, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 6; records 51–100 of 260 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1205091758?year=2021&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2021
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30
260 matching records · $8,764.77 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–100 of 260.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Taiho Oncology, Inc. | $20.17 | 10/19/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 843378833 | CMS |
| Daiichi Sankyo Inc. | $25.37 | 10/18/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 836330031 | CMS |
| Novartis Pharmaceuticals Corporation | $83.33 | 10/16/2021 | Long term medical supply or device loan | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 812740475 | CMS |
| Ipsen Biopharmaceuticals, Inc | $12.84 | 10/15/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 841911545 | CMS |
| GENZYME CORPORATION | $23.69 | 10/13/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 843638399 | CMS |
| Janssen Biotech, Inc. | $120.45 | 10/13/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 787982939 | CMS |
| Novartis Pharmaceuticals Corporation | $16.06 | 10/12/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 812740443 | CMS |
| ARRAY BIOPHARMA INC | $15.75 | 10/11/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 833183451 | CMS |
| EMD Serono, Inc. | $115.56 | 10/06/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 849154567 | CMS |
| Pharmacyclics LLC, An AbbVie Company | $23.89 | 10/06/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 781017097 | CMS |
| PFIZER INC. | $13.46 | 10/04/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 832907103 | CMS |
| Eisai Inc. | $17.10 | 10/01/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818017529 | CMS |
| Novartis Pharmaceuticals Corporation | $17.94 | 09/30/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 812740447 | CMS |
| GlaxoSmithKline, LLC. | $124.00 | 09/29/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 802974689 | CMS |
| Lilly USA, LLC | $15.18 | 09/28/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818802203 | CMS |
| GENZYME CORPORATION | $24.53 | 09/27/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 843638393 | CMS |
| Amgen Inc. | $22.44 | 09/24/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 826451397 | CMS |
| Celgene Corporation | $161.92 | 09/23/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 783717231 | CMS |
| Novartis Pharmaceuticals Corporation | $10.18 | 09/23/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 812740449 | CMS |
| Celgene Corporation | $22.36 | 09/22/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 783717229 | CMS |
| Daiichi Sankyo Inc. | $100.00 | 09/22/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 836324679 | CMS |
| AstraZeneca Pharmaceuticals LP | $13.44 | 09/21/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834346689 | CMS |
| Incyte Corporation | $17.69 | 09/20/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 835546997 | CMS |
| Nevro Corp. | $19.59 | 09/17/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 832301295 | CMS |
| Genentech USA, Inc. | $17.37 | 09/16/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 835987835 | CMS |
| Novartis Pharmaceuticals Corporation | $83.33 | 09/16/2021 | Long term medical supply or device loan | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 812740473 | CMS |
| E.R. Squibb & Sons, L.L.C. | $2.69 | 09/15/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 783598271 | CMS |
| Incyte Corporation | $99.22 | 09/15/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 835547065 | CMS |
| Janssen Biotech, Inc. | $20.98 | 09/15/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 787982949 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $13.71 | 09/14/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 789129613 | CMS |
| Merck Sharp & Dohme Corporation | $19.40 | 09/13/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 848406487 | CMS |
| Pharmacyclics LLC, An AbbVie Company | $17.72 | 09/10/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 781017095 | CMS |
| Amgen Inc. | $18.36 | 09/09/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 826451391 | CMS |
| E.R. Squibb & Sons, L.L.C. | $115.68 | 09/09/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 783654159 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $12.73 | 09/08/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 763658674 | CMS |
| Celgene Corporation | $15.34 | 09/08/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 783717227 | CMS |
| AstraZeneca Pharmaceuticals LP | $16.94 | 09/07/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834343997 | CMS |
| Myovant Sciences Inc. | $115.40 | 09/07/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834961731 | CMS |
| Novartis Pharmaceuticals Corporation | $16.40 | 09/07/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 812740441 | CMS |
| Eisai Inc. | $21.70 | 09/03/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818057334 | CMS |
| TG THERAPEUTICS, INC. | $24.11 | 09/02/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 844040377 | CMS |
| Astellas Pharma US Inc | $15.05 | 09/01/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 821388891 | CMS |
| E.R. Squibb & Sons, L.L.C. | $115.56 | 09/01/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 783654167 | CMS |
| Incyte Corporation | $15.50 | 08/31/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 835546987 | CMS |
| Seagen Inc. | $14.06 | 08/30/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 832158737 | CMS |
| Novartis Pharmaceuticals Corporation | $19.16 | 08/26/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 812740445 | CMS |
| Kite Pharma, Inc. | $85.26 | 08/25/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 844416003 | CMS |
| Astellas Pharma US Inc | $15.92 | 08/24/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 821388885 | CMS |
| AstraZeneca Pharmaceuticals LP | $24.21 | 08/19/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834347507 | CMS |
| E.R. Squibb & Sons, L.L.C. | $5.17 | 08/19/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 783598259 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $150.00 | 1 |
| PY2025 | Principal investigator | $419,595.67 | 125 |
| PY2024 | Principal investigator | $260,104.53 | 173 |
| PY2023 | Principal investigator | $194,397.52 | 62 |
| PY2022 | Principal investigator | $150,869.81 | 31 |
| PY2021 | Recipient | $1,417.45 | 1 |
| PY2021 | Principal investigator | $239,699.09 | 27 |
| PY2020 | Recipient | $4,360.00 | 1 |
| PY2020 | Principal investigator | $85,814.19 | 6 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
126 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $1,000.00 | 12/10/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane Trastuzumab and Pertuzumab in HER2-positive First-line Metastatic Breast Cancer (DESTINY-Breast09) | No dispute reported | 06/30/2026 | 1185547707 |
| Principal investigator 1 | PFIZER INC. | $27.54 | 12/08/2025 | Non-covered Recipient Entity Cancer Care Centers of Brevard Inc | AN INTERVENTIONAL PHASE 3 DOUBLEBLIND RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN TREATMENTNAÏVE PARTICIPANTS WITH METASTATIC COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228706757 |
| Principal investigator 1 | PFIZER INC. | $27.54 | 12/08/2025 | Non-covered Recipient Entity Cancer Care Centers of Brevard Inc | AN INTERVENTIONAL PHASE 3 DOUBLEBLIND RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN TREATMENTNAÏVE PARTICIPANTS WITH METASTATIC COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228706759 |
| Principal investigator 1 | PFIZER INC. | $27.54 | 12/08/2025 | Non-covered Recipient Entity Cancer Care Centers of Brevard Inc | AN INTERVENTIONAL PHASE 3 DOUBLEBLIND RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN TREATMENTNAÏVE PARTICIPANTS WITH METASTATIC COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228706761 |
| Principal investigator 1 | PFIZER INC. | $26.00 | 12/08/2025 | Non-covered Recipient Entity Cancer Care Centers of Brevard Inc | AN INTERVENTIONAL PHASE 3 DOUBLEBLIND RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN TREATMENTNAÏVE PARTICIPANTS WITH METASTATIC COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228706863 |
| Principal investigator 1 | PFIZER INC. | $27.54 | 12/08/2025 | Non-covered Recipient Entity Cancer Care Centers of Brevard Inc | AN INTERVENTIONAL PHASE 3 DOUBLEBLIND RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN TREATMENTNAÏVE PARTICIPANTS WITH METASTATIC COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228706937 |
| Principal investigator 1 | PFIZER INC. | $27.54 | 12/08/2025 | Non-covered Recipient Entity Cancer Care Centers of Brevard Inc | AN INTERVENTIONAL PHASE 3 DOUBLEBLIND RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN TREATMENTNAÏVE PARTICIPANTS WITH METASTATIC COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228706939 |
| Principal investigator 1 | PFIZER INC. | $3,187.76 | 12/08/2025 | Non-covered Recipient Entity Cancer Care Centers of Brevard Inc | AN INTERVENTIONAL PHASE 3 DOUBLEBLIND RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN TREATMENTNAÏVE PARTICIPANTS WITH METASTATIC COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228706941 |
| Principal investigator 1 | PFIZER INC. | $26.00 | 12/08/2025 | Non-covered Recipient Entity Cancer Care Centers of Brevard Inc | AN INTERVENTIONAL PHASE 3 DOUBLEBLIND RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN TREATMENTNAÏVE PARTICIPANTS WITH METASTATIC COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228707876 |
| Principal investigator 1 | PFIZER INC. | $27.54 | 12/08/2025 | Non-covered Recipient Entity Cancer Care Centers of Brevard Inc | AN INTERVENTIONAL PHASE 3 DOUBLEBLIND RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN TREATMENTNAÏVE PARTICIPANTS WITH METASTATIC COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228707878 |
| Principal investigator 1 | PFIZER INC. | $26.00 | 12/08/2025 | Non-covered Recipient Entity Cancer Care Centers of Brevard Inc | AN INTERVENTIONAL PHASE 3 DOUBLEBLIND RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN TREATMENTNAÏVE PARTICIPANTS WITH METASTATIC COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228707880 |
| Principal investigator 1 | BioNTech SE | $245.00 | 12/01/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | BNT327-03 | No dispute reported | 06/30/2026 | 1249019328 |
| Principal investigator 1 | BioNTech SE | $245.00 | 12/01/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | BNT327-03 | No dispute reported | 06/30/2026 | 1249019580 |
| Principal investigator 1 | Eli Lilly and Company | $90.00 | 11/20/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | EMBER-4: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ADJUVANT IMLUNESTRANT VS STANDARD ADJUVANT ENDOCRINE THERAPY IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED 2 TO 5 YEARS OF ADJUVANT ENDOCRINE THERAPY FOR ER+, HER2- EARLY BREAST CANCER WITH AN INCREASED RISK OF RECURRENCE | No dispute reported | 06/30/2026 | 1187891602 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,125.00 | 11/13/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U304 | No dispute reported | 06/30/2026 | 1223387493 |
| Principal investigator 1 | BioNTech SE | $92.00 | 11/01/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | BNT327-03 | No dispute reported | 06/30/2026 | 1249019570 |
| Principal investigator 1 | BioNTech SE | $92.00 | 11/01/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | BNT327-03 | No dispute reported | 06/30/2026 | 1249019576 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,125.00 | 10/23/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388265 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $956.00 | 10/15/2025 | Non-covered Recipient Entity Cancer Care Centers Of Brevard Melbourne | DS1062-A-U304 | No dispute reported | 06/30/2026 | 1223365263 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $956.00 | 10/15/2025 | Non-covered Recipient Entity Cancer Care Centers Of Brevard Melbourne | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223365267 |
| Principal investigator 1 | PFIZER INC. | $957.00 | 10/15/2025 | Non-covered Recipient Entity CANCER CARE CENTERS OF BREVARD INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228726426 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,774.00 | 10/14/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U304 | No dispute reported | 06/30/2026 | 1223387491 |
| Principal investigator 1 | PFIZER INC. | $1,125.00 | 09/15/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228749102 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,125.00 | 08/27/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U304 | No dispute reported | 06/30/2026 | 1223387487 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,125.00 | 08/27/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388261 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $588.00 | 08/27/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388263 |
| Principal investigator 1 | Janssen Scientific Affairs, LLC | $16.67 | 08/15/2025 | Non-covered Recipient Entity Cancer Care Centers Of Brevard Melbourne Pine-Medical Oncology | MYLUNG Consortium Part 3: Observational Study (MYLUNG) | No dispute reported | 06/30/2026 | 1174941475 |
| Principal investigator 1 | Janssen Scientific Affairs, LLC | $16.67 | 08/15/2025 | Non-covered Recipient Entity Cancer Care Centers Of Brevard Melbourne Pine-Medical Oncology | MYLUNG Consortium Part 3: Observational Study (MYLUNG) | No dispute reported | 06/30/2026 | 1174941498 |
| Principal investigator 1 | Janssen Scientific Affairs, LLC | $16.67 | 08/15/2025 | Non-covered Recipient Entity Cancer Care Centers Of Brevard Melbourne Pine-Medical Oncology | MYLUNG Consortium Part 3: Observational Study (MYLUNG) | No dispute reported | 06/30/2026 | 1174941579 |
| Principal investigator 1 | Janssen Scientific Affairs, LLC | $16.67 | 08/15/2025 | Non-covered Recipient Entity Cancer Care Centers Of Brevard Melbourne Pine-Medical Oncology | MYLUNG Consortium Part 3: Observational Study (MYLUNG) | No dispute reported | 06/30/2026 | 1174941591 |
| Principal investigator 1 | Janssen Scientific Affairs, LLC | $16.67 | 08/15/2025 | Non-covered Recipient Entity Cancer Care Centers Of Brevard Melbourne Pine-Medical Oncology | MYLUNG Consortium Part 3: Observational Study (MYLUNG) | No dispute reported | 06/30/2026 | 1174941607 |
| Principal investigator 1 | Janssen Scientific Affairs, LLC | $16.67 | 08/15/2025 | Non-covered Recipient Entity Cancer Care Centers Of Brevard Melbourne Pine-Medical Oncology | MYLUNG Consortium Part 3: Observational Study (MYLUNG) | No dispute reported | 06/30/2026 | 1174941697 |
| Principal investigator 1 | PFIZER INC. | $1,641.00 | 08/15/2025 | Non-covered Recipient Entity CANCER CARE CENTERS OF BREVARD INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228720619 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 08/15/2025 | Non-covered Recipient Entity CANCER CARE CENTERS OF BREVARD INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228744375 |
| Principal investigator 1 | PFIZER INC. | $723.00 | 08/11/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228766741 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $6,058.00 | 08/06/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U304 | No dispute reported | 06/30/2026 | 1223387489 |
| Principal investigator 1 | Genentech, Inc. | $1,500.00 | 07/21/2025 | Non-covered Recipient Entity UNITED STATES ONCOLOGY RESEARCH LLC | Tiragolumab Tecentriq vs Durvalumab in Unresectable Stage III NSCLC | No dispute reported | 06/30/2026 | 1211676413 |
| Principal investigator 1 | Janssen Scientific Affairs, LLC | $16.67 | 07/15/2025 | Non-covered Recipient Entity Cancer Care Centers Of Brevard - Melbourne Pine | MYLUNG Consortium Part 3: Observational Study (MYLUNG) | No dispute reported | 06/30/2026 | 1174941554 |
| Principal investigator 1 | PFIZER INC. | $957.00 | 07/15/2025 | Non-covered Recipient Entity CANCER CARE CENTERS OF BREVARD INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228743942 |
| Principal investigator 1 | PFIZER INC. | $2,518.00 | 06/16/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228790391 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,125.00 | 06/13/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U304 | No dispute reported | 06/30/2026 | 1223387485 |
| Principal investigator 1 | PFIZER INC. | $1,125.00 | 05/28/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228723076 |
| Principal investigator 1 | Genentech, Inc. | $4,089.00 | 05/19/2025 | Non-covered Recipient Entity UNITED STATES ONCOLOGY RESEARCH LLC | Tiragolumab Tecentriq vs Durvalumab in Unresectable Stage III NSCLC | No dispute reported | 06/30/2026 | 1211676346 |
| Principal investigator 1 | Genentech, Inc. | $1,350.00 | 05/12/2025 | Non-covered Recipient Entity US Oncology Research, LLC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211681522 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $16,534.80 | 05/07/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE | A Phase III, Randomized,Open Label,Multi Center,Global Study of Volrustomig as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma,Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy | No dispute reported | 06/30/2026 | 1185547699 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $25,712.07 | 04/30/2025 | Non-covered Recipient Entity CANCER CARE CENTERS OF BREVARD | A Phase III, Randomized,Open Label,Multi Center,Global Study of Volrustomig as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma,Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy | No dispute reported | 06/30/2026 | 1185547697 |
| Principal investigator 1 | Eli Lilly and Company | $18,227.00 | 04/29/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | LIBRETTO-432: A PLACEBO-CONTROLLED DOUBLE-BLINDED RANDOMIZED PHASE 3 STUDY OF ADJUVANT SELPERCATINIB FOLLOWING DEFINITIVE LOCOREGIONAL TREATMENT IN PARTICIPANTS WITH STAGE IB-IIIA RET FUSION-POSITIVE NSCLC | No dispute reported | 06/30/2026 | 1187892426 |
| Principal investigator 1 | Genentech, Inc. | $1,500.00 | 04/23/2025 | Non-covered Recipient Entity UNITED STATES ONCOLOGY RESEARCH LLC | Tiragolumab Tecentriq vs Durvalumab in Unresectable Stage III NSCLC | No dispute reported | 06/30/2026 | 1211676312 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $956.00 | 04/15/2025 | Non-covered Recipient Entity Cancer Care Centers Of Brevard Melbourne | DS1062-A-U304 | No dispute reported | 06/30/2026 | 1223365261 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $956.00 | 04/15/2025 | Non-covered Recipient Entity Cancer Care Centers Of Brevard Melbourne | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223365265 |
| Principal investigator 1 | Janssen Scientific Affairs, LLC | $16.67 | 04/15/2025 | Non-covered Recipient Entity Cancer Care Centers Of Brevard Melbourne Pine-Medi | MYLUNG Consortium Part 3: Observational Study (MYLUNG) | No dispute reported | 06/30/2026 | 1174941633 |
| Principal investigator 1 | Janssen Scientific Affairs, LLC | $16.67 | 04/15/2025 | Non-covered Recipient Entity Cancer Care Centers Of Brevard Melbourne Pine-Medi | MYLUNG Consortium Part 3: Observational Study (MYLUNG) | No dispute reported | 06/30/2026 | 1174941685 |
| Principal investigator 1 | PFIZER INC. | $957.00 | 04/15/2025 | Non-covered Recipient Entity CANCER CARE CENTERS OF BREVARD INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228745173 |
| Principal investigator 1 | PFIZER INC. | $860.00 | 04/15/2025 | Non-covered Recipient Entity CANCER CARE CENTERS OF BREVARD INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228745952 |
| Principal investigator 1 | PFIZER INC. | $250.00 | 04/15/2025 | Non-covered Recipient Entity CANCER CARE CENTERS OF BREVARD INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228746511 |
| Principal investigator 1 | Genentech, Inc. | $2,168.00 | 04/08/2025 | Non-covered Recipient Entity UNITED STATES ONCOLOGY RESEARCH LLC | Tiragolumab Tecentriq vs Durvalumab in Unresectable Stage III NSCLC | No dispute reported | 06/30/2026 | 1211676333 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $590.00 | 03/27/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U304 | No dispute reported | 06/30/2026 | 1223387473 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,125.00 | 03/27/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U304 | No dispute reported | 06/30/2026 | 1223387475 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $590.00 | 03/27/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U304 | No dispute reported | 06/30/2026 | 1223387477 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $590.00 | 03/27/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U304 | No dispute reported | 06/30/2026 | 1223387479 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,125.00 | 03/27/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U304 | No dispute reported | 06/30/2026 | 1223387481 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $590.00 | 03/27/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U304 | No dispute reported | 06/30/2026 | 1223387483 |
| Principal investigator 1 | PFIZER INC. | $9,011.00 | 03/24/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228795253 |
| Principal investigator 1 | Eli Lilly and Company | $565.00 | 03/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE CLINICAL TRIALS LLC | EMBER-4: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ADJUVANT IMLUNESTRANT VS STANDARD ADJUVANT ENDOCRINE THERAPY IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED 2 TO 5 YEARS OF ADJUVANT ENDOCRINE THERAPY FOR ER+, HER2- EARLY BREAST CANCER WITH AN INCREASED RISK OF RECURRENCE | No dispute reported | 06/30/2026 | 1187887098 |
| Principal investigator 1 | Janssen Scientific Affairs, LLC | $16.67 | 03/15/2025 | Non-covered Recipient Entity Cancer Care Centers Of Brevard-Melbourne | MYLUNG Consortium Part 3: Observational Study (MYLUNG) | No dispute reported | 06/30/2026 | 1174941563 |
| Principal investigator 1 | Janssen Scientific Affairs, LLC | $150.00 | 03/15/2025 | Non-covered Recipient Entity Cancer Care Centers Of Brevard-Melbourne | MYLUNG Consortium Part 3: Observational Study (MYLUNG) | No dispute reported | 06/30/2026 | 1174941647 |
| Principal investigator 1 | PFIZER INC. | $750.00 | 03/15/2025 | Non-covered Recipient Entity CANCER CARE CENTERS OF BREVARD INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228744710 |
| Principal investigator 1 | PFIZER INC. | $3,231.00 | 03/15/2025 | Non-covered Recipient Entity CANCER CARE CENTERS OF BREVARD INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228749168 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,125.00 | 03/06/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388259 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $3,000.00 | 03/05/2025 | Non-covered Recipient Entity THE US ONCOLOGY NETWORK | Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane Trastuzumab and Pertuzumab in HER2-positive First-line Metastatic Breast Cancer (DESTINY-Breast09) | No dispute reported | 06/30/2026 | 1185547703 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,125.00 | 02/27/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387229 |
| Recipient | Eli Lilly and Company | $150.00 | 02/15/2025 | Covered Recipient Physician | Not supplied | No dispute reported | 06/30/2026 | 1187873605 |
| Principal investigator 1 | Janssen Scientific Affairs, LLC | $150.00 | 02/15/2025 | Non-covered Recipient Entity Cancer Care Centers Of Brevard-Melbourne | MYLUNG Consortium Part 3: Observational Study (MYLUNG) | No dispute reported | 06/30/2026 | 1174941484 |
| Principal investigator 1 | Janssen Scientific Affairs, LLC | $150.00 | 02/15/2025 | Non-covered Recipient Entity Cancer Care Centers Of Brevard-Melbourne | MYLUNG Consortium Part 3: Observational Study (MYLUNG) | No dispute reported | 06/30/2026 | 1174941509 |
| Principal investigator 1 | Janssen Scientific Affairs, LLC | $150.00 | 02/15/2025 | Non-covered Recipient Entity Cancer Care Centers Of Brevard-Melbourne | MYLUNG Consortium Part 3: Observational Study (MYLUNG) | No dispute reported | 06/30/2026 | 1174941528 |
| Principal investigator 1 | Janssen Scientific Affairs, LLC | $150.00 | 02/15/2025 | Non-covered Recipient Entity Cancer Care Centers Of Brevard-Melbourne | MYLUNG Consortium Part 3: Observational Study (MYLUNG) | No dispute reported | 06/30/2026 | 1174941541 |
| Principal investigator 1 | Janssen Scientific Affairs, LLC | $16.67 | 02/15/2025 | Non-covered Recipient Entity Cancer Care Centers Of Brevard-Melbourne | MYLUNG Consortium Part 3: Observational Study (MYLUNG) | No dispute reported | 06/30/2026 | 1174941657 |
| Principal investigator 1 | Janssen Scientific Affairs, LLC | $150.00 | 02/15/2025 | Non-covered Recipient Entity Cancer Care Centers Of Brevard-Melbourne | MYLUNG Consortium Part 3: Observational Study (MYLUNG) | No dispute reported | 06/30/2026 | 1174941675 |
| Principal investigator 1 | Janssen Scientific Affairs, LLC | $150.00 | 02/15/2025 | Non-covered Recipient Entity Cancer Care Centers Of Brevard-Melbourne | MYLUNG Consortium Part 3: Observational Study (MYLUNG) | No dispute reported | 06/30/2026 | 1174941707 |
| Principal investigator 1 | Janssen Scientific Affairs, LLC | $150.00 | 02/15/2025 | Non-covered Recipient Entity Cancer Care Centers Of Brevard-Melbourne | MYLUNG Consortium Part 3: Observational Study (MYLUNG) | No dispute reported | 06/30/2026 | 1174941718 |
| Principal investigator 1 | PFIZER INC. | $330.00 | 02/15/2025 | Non-covered Recipient Entity CANCER CARE CENTERS OF BREVARD INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228743947 |
| Principal investigator 1 | PFIZER INC. | $330.00 | 02/15/2025 | Non-covered Recipient Entity CANCER CARE CENTERS OF BREVARD INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228744132 |
| Principal investigator 1 | PFIZER INC. | $281.00 | 02/15/2025 | Non-covered Recipient Entity CANCER CARE CENTERS OF BREVARD INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228744312 |
| Principal investigator 1 | PFIZER INC. | $330.00 | 02/15/2025 | Non-covered Recipient Entity CANCER CARE CENTERS OF BREVARD INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228744316 |
| Principal investigator 1 | PFIZER INC. | $750.00 | 02/15/2025 | Non-covered Recipient Entity CANCER CARE CENTERS OF BREVARD INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228744383 |
| Principal investigator 1 | PFIZER INC. | $2,147.00 | 02/15/2025 | Non-covered Recipient Entity CANCER CARE CENTERS OF BREVARD INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228744659 |
| Principal investigator 1 | PFIZER INC. | $2,200.00 | 02/15/2025 | Non-covered Recipient Entity CANCER CARE CENTERS OF BREVARD INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228744830 |
| Principal investigator 1 | PFIZER INC. | $50.00 | 02/15/2025 | Non-covered Recipient Entity CANCER CARE CENTERS OF BREVARD INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228745726 |
| Principal investigator 1 | PFIZER INC. | $2,931.00 | 02/15/2025 | Non-covered Recipient Entity CANCER CARE CENTERS OF BREVARD INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228747838 |
| Principal investigator 1 | PFIZER INC. | $330.00 | 02/15/2025 | Non-covered Recipient Entity CANCER CARE CENTERS OF BREVARD INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228747842 |
| Principal investigator 1 | PFIZER INC. | $1,843.00 | 02/15/2025 | Non-covered Recipient Entity CANCER CARE CENTERS OF BREVARD INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228747943 |
| Principal investigator 1 | PFIZER INC. | $2,042.00 | 02/15/2025 | Non-covered Recipient Entity CANCER CARE CENTERS OF BREVARD INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228747947 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $6,451.00 | 02/13/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U304 | No dispute reported | 06/30/2026 | 1223387197 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $590.00 | 02/13/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U304 | No dispute reported | 06/30/2026 | 1223387199 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,242.00 | 02/13/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U304 | No dispute reported | 06/30/2026 | 1223387201 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $590.00 | 02/13/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U304 | No dispute reported | 06/30/2026 | 1223387203 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $590.00 | 02/13/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U304 | No dispute reported | 06/30/2026 | 1223387205 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $90.00 | 02/13/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U304 | No dispute reported | 06/30/2026 | 1223387207 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,242.00 | 02/13/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U304 | No dispute reported | 06/30/2026 | 1223387209 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,125.00 | 02/13/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U304 | No dispute reported | 06/30/2026 | 1223387211 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $236.00 | 02/13/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U304 | No dispute reported | 06/30/2026 | 1223387213 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,242.00 | 02/13/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U304 | No dispute reported | 06/30/2026 | 1223387215 |
| Principal investigator 1 | Eli Lilly and Company | $0.04 | 02/06/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE CLINICAL TRIALS LLC | EMBER-4: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ADJUVANT IMLUNESTRANT VS STANDARD ADJUVANT ENDOCRINE THERAPY IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED 2 TO 5 YEARS OF ADJUVANT ENDOCRINE THERAPY FOR ER+, HER2- EARLY BREAST CANCER WITH AN INCREASED RISK OF RECURRENCE | No dispute reported | 06/30/2026 | 1187886856 |
| Principal investigator 1 | Genentech, Inc. | $1,350.00 | 02/05/2025 | Non-covered Recipient Entity US Oncology Research, LLC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211681550 |
| Principal investigator 1 | Genentech, Inc. | $1,500.00 | 02/04/2025 | Non-covered Recipient Entity UNITED STATES ONCOLOGY RESEARCH LLC | Tiragolumab Tecentriq vs Durvalumab in Unresectable Stage III NSCLC | No dispute reported | 06/30/2026 | 1211676261 |
| Principal investigator 1 | PFIZER INC. | $13,605.00 | 02/03/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228791554 |
| Principal investigator 1 | Eli Lilly and Company | $0.14 | 01/28/2025 | Non-covered Recipient Entity CANCER CARE CENTERS OF BREVARD, INC. | LIBRETTO-432: A PLACEBO-CONTROLLED DOUBLE-BLINDED RANDOMIZED PHASE 3 STUDY OF ADJUVANT SELPERCATINIB FOLLOWING DEFINITIVE LOCOREGIONAL TREATMENT IN PARTICIPANTS WITH STAGE IB-IIIA RET FUSION-POSITIVE NSCLC | No dispute reported | 06/30/2026 | 1187874607 |
| Principal investigator 1 | Eli Lilly and Company | $65,656.00 | 01/21/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | EMBER-4: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ADJUVANT IMLUNESTRANT VS STANDARD ADJUVANT ENDOCRINE THERAPY IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED 2 TO 5 YEARS OF ADJUVANT ENDOCRINE THERAPY FOR ER+, HER2- EARLY BREAST CANCER WITH AN INCREASED RISK OF RECURRENCE | No dispute reported | 06/30/2026 | 1187893264 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $22,060.65 | 01/17/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase III, Randomized,Open Label,Multi Center,Global Study of Volrustomig as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma,Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy | No dispute reported | 06/30/2026 | 1185547701 |
| Principal investigator 1 | Amgen Inc. | $1,483.36 | 01/15/2025 | Non-covered Recipient Entity CANCER CARE CENTERS OF BREVARD, INC. | Molecularly-Informed Lung Cancer Treatment in a Community Cancer Network: A Pragmatic Consortium | No dispute reported | 06/30/2026 | 1246639885 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $680.00 | 01/15/2025 | Non-covered Recipient Entity CANCER CARE CENTERS OF BREVARD | Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane Trastuzumab and Pertuzumab in HER2-positive First-line Metastatic Breast Cancer (DESTINY-Breast09) | No dispute reported | 06/30/2026 | 1185547695 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $2,040.00 | 01/15/2025 | Non-covered Recipient Entity CANCER CARE CENTERS OF BREVARD | A Retrospective Analysis of Biomarker Testing Variance and Treatment Patterns among Patients with Metastatic Non-Small Cell Lung Cancer (mNSCLC) in the US Oncology Network Community | No dispute reported | 06/30/2026 | 1185547705 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $956.00 | 01/15/2025 | Non-covered Recipient Entity Cancer Care Centers Of Brevard Melbourne | DS1062-A-U304 | No dispute reported | 06/30/2026 | 1223365269 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $956.00 | 01/15/2025 | Non-covered Recipient Entity Cancer Care Centers Of Brevard Melbourne | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223365271 |
| Principal investigator 1 | Eli Lilly and Company | $956.00 | 01/15/2025 | Non-covered Recipient Entity CANCER CARE CENTERS OF BREVARD, INC. | EMONARCHER: A RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF ABEMACICLIB PLUS STANDARD ADJUVANT ENDOCRINE THERAPY IN PARTICIPANTS WITH HIGH-RISK, NODE-POSITIVE, HR+, HER2+ EARLY BREAST CANCER WHO HAVE COMPLETED ADJUVANT HER2-TARGETED THERAPY | No dispute reported | 06/30/2026 | 1187874609 |
| Principal investigator 1 | Eli Lilly and Company | $105,839.00 | 01/15/2025 | Non-covered Recipient Entity CANCER CARE CENTERS OF BREVARD, INC. | EMBER-4: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ADJUVANT IMLUNESTRANT VS STANDARD ADJUVANT ENDOCRINE THERAPY IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED 2 TO 5 YEARS OF ADJUVANT ENDOCRINE THERAPY FOR ER+, HER2- EARLY BREAST CANCER WITH AN INCREASED RISK OF RECURRENCE | No dispute reported | 06/30/2026 | 1187875431 |
| Principal investigator 1 | Eli Lilly and Company | $31,772.00 | 01/15/2025 | Non-covered Recipient Entity CANCER CARE CENTERS OF BREVARD, INC. | LIBRETTO-432: A PLACEBO-CONTROLLED DOUBLE-BLINDED RANDOMIZED PHASE 3 STUDY OF ADJUVANT SELPERCATINIB FOLLOWING DEFINITIVE LOCOREGIONAL TREATMENT IN PARTICIPANTS WITH STAGE IB-IIIA RET FUSION-POSITIVE NSCLC | No dispute reported | 06/30/2026 | 1187876523 |
| Principal investigator 1 | Eli Lilly and Company | $1,549.95 | 01/15/2025 | Non-covered Recipient Entity CANCER CARE CENTERS OF BREVARD, INC. | Not supplied | No dispute reported | 06/30/2026 | 1187880619 |
| Principal investigator 1 | Janssen Scientific Affairs, LLC | $150.00 | 01/15/2025 | Non-covered Recipient Entity Cancer Care Centers Of Brevard-Melbourne | MYLUNG Consortium Part 3: Observational Study (MYLUNG) | No dispute reported | 06/30/2026 | 1174941520 |
| Principal investigator 1 | Janssen Scientific Affairs, LLC | $150.00 | 01/15/2025 | Non-covered Recipient Entity Cancer Care Centers Of Brevard-Melbourne | MYLUNG Consortium Part 3: Observational Study (MYLUNG) | No dispute reported | 06/30/2026 | 1174941621 |
| Principal investigator 1 | PFIZER INC. | $3,231.00 | 01/15/2025 | Non-covered Recipient Entity CANCER CARE CENTERS OF BREVARD INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228743939 |
| Principal investigator 1 | PFIZER INC. | $281.00 | 01/15/2025 | Non-covered Recipient Entity CANCER CARE CENTERS OF BREVARD INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228744181 |
| Principal investigator 1 | PFIZER INC. | $151.00 | 01/15/2025 | Non-covered Recipient Entity CANCER CARE CENTERS OF BREVARD INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228744308 |
| Principal investigator 1 | PFIZER INC. | $750.00 | 01/15/2025 | Non-covered Recipient Entity CANCER CARE CENTERS OF BREVARD INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228744379 |
| Principal investigator 1 | PFIZER INC. | $957.00 | 01/15/2025 | Non-covered Recipient Entity CANCER CARE CENTERS OF BREVARD INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228746902 |
| Principal investigator 1 | Eli Lilly and Company | $1.29 | 01/06/2025 | Non-covered Recipient Entity CANCER CARE CENTERS OF BREVARD, INC. | EMBER-4: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ADJUVANT IMLUNESTRANT VS STANDARD ADJUVANT ENDOCRINE THERAPY IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED 2 TO 5 YEARS OF ADJUVANT ENDOCRINE THERAPY FOR ER+, HER2- EARLY BREAST CANCER WITH AN INCREASED RISK OF RECURRENCE | No dispute reported | 06/30/2026 | 1187878255 |